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Background: Congenital Adrenal Hyperplasia (CAH, the inherited inability to synthesize cortisol) is one of 
the most common (1 in 10000 to 1 in 15000) autosomal recessive disorders. More than 95% of cases of CAH 
are caused by 21-hydroxylase deficiency (21-OHD). Females with severe, classic 21-OHD are exposed to 
excess androgens prenatally and are born with virilized external genitalia. Most patients cannot synthesize 
sufficient aldosterone to maintain sodium balance and may develop potentially fatal salt wasting crisis if not 
treated.  Methods: We applied allele specific PCR to detect the eight common mutations in the CYP21 gene 
in patients. Fifty unrelated patients with symptoms of classical CAH were studied. Results and Conclusion: 
Seventy percent of our subjects had these mutations. The most frequent mutations were found to be I2G and 
del-8bp (28% and 13%, respectively). The frequencies of other alleles were as following: I172N, 9%; V281L, 
3%; exon 6 cluster (I236N, V237E and M239K), 4%; Q318X, 9%; R356W, 5%; and P30L, 0%. The 
frequency of mutations did not differ substantially from other ethnics, however, a higher rate of del-8 bp 
(13%) was found in our population. The aim of this study was to detect common mutations for setting up a 
molecular method for prenatal diagnosis.  Iran. Biomed. J. 12 (1): 49-53, 2008 
 





ongenital adrenal hyperplasia (CAH) 
encompasses a group of genetic disorders of 
adrenal steroidogenesis characterized by 
impaired activity of one of the enzymes required for 
cortisol biosynthesis [1]. Steroid 21-hydroxylase 
deficiency (21-OHD) is present in more than 95% of 
the patients with CAH [2]. The incidence of severe 
form is one in 10,000 to one in 15,000 among 
Caucasians [2]. The prevalence of non-classic 21-
OHD is estimated to be one in 1700 in general 
population [3]. Based on newborn screening data, 
the carrier frequency of CAH in the general 
population has estimated to be 1:55 [4]. Steroid 21-
hydroxylase normally converts 17-hydroxy-
progestrone into 11-deoxyortisol and progesterone 
into 11-deoxycorticosterone. These steroids are 
subsequently converted into cortisol and 
aldosterone, respectively [5]. Classical 21-OHD is 
the most common cause of ambiguous genitalia in 
female [1]. It is also one of the few disorders in 
which prenatal diagnosis and treatment to prevent a 
birth defect is feasible and effective [1, 2]. The gene 
for adrenal 21-hydroxylase, CYP21 is located about 
30 kb from an inactive cognate gene, CYP21P, on 
short arm of chromosome 6 in the area of the HLA 
genes [6]. This inactive pseudogene is 98% 
homologous to the active gene. During meiosis, 
because of high homology between pseudogene and 
active gene, a gene conversion appears to occur that 
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Table 1. Annealing temperature and primers used for PCR. 
Mutation Exon 6 
cluster 
V281L I172N 8 bp 
deletion 
R356W Q318X I2G P30L 
Forward Primer Ex6na and 
Ex6ma 














Reverse Primer Ex3ns Ex6ns Ex6na Ex6na Ex6ns Ex6ns Ex3na Ex6ns 
Annealing Temperature 60°C 63°C 65°C 60°C 63°C 63°C 69°C 67°C 
PCR Product (bp) 710 330 420 710 720 650 80 1300 
   N, normal; m, mutant; s, sense; a, antisense; Ex, exon; I, intron 
 
 
gene to CYP21 gene and causes either complete or 
partial inactivation of 21-hydroxylase activity [7]. 
To date, deletion or conversion of the CYP21 
gene, pseudogene-derived point mutations and some 
other mutations have been reported [1]. The eight 
common pseudogene-derived point mutations have 
been studied in most populations [2]. The 
deleterious mutations in CYP21P include an A to G 
substitution 13 nucleotides before the end of intron 2 
that results in aberrant splicing of pre-mRNA, an 8-
nt deletion in exon 3 and a 1-nt insertion in exon 7, 
each of them shifts the reading frame of translation, 
and a nonsense mutation in codon 318 of exon 8. 
There are also 8 missense mutations in CYP21P, 7 of 
them have been observed in patients with 21-OHD. 
Because particular mutations occur in many 
unrelated kindred, each mutation, and the degree of 
enzymatic compromise which it causes may be 
correlated with the different clinical forms of 21-
OHD. Mutation A (or C) to G near the end of intron 
2 (12G) accounts for 20 to 25 percent of mutations 
in most populations. The other point mutations have 
different frequency in different populations. The 
objective of this study was to determine the 




MATERIALS AND METHODS 
 
At first, fifty individuals were diagnosed clinically 
by pediatric endocrinologist and genetic counseling 
was performed for each family. In this study, 
informed consent for the molecular tests was 
provided by those families. DNA samples were 
extracted according to the standard protocol [8]. The 
eight most common mutations analyzed in the 
CYP21 gene were 12G, 1172N, V281L, P30L, exon 
6 cluster, Q318X, R356W and 8 bp deletion in exon 
3 (G110∆ 8 nt). In this study, we used allele specific 
PCR for detection of mutations [9]. Different PCR 
conditions (Table 1) were required to analyze all 
eight most common mutation sites. For each  
mutation site in question, two PCR were performed: 
one reaction detected the normal allele, and other 
one detected the mutant allele. Each reaction 
contained either a normal or mutant type primer 
(Genefanavaran, Tehran, Iran) used with common 
primer which amplified only the CYP21 gene and 
not the pseudogene (CYP21P) containing these eight 
mutations. Primer sequences, mutation names and 
size of fragments amplified by PCR have been 
depicted in Table 2. The positive DNA controls were 
provided from Erasmus University, Netherlands. 
Finally, PCR products directly were run on 8% 
polyacrylamide gel electrophoresis, separately for 
each exon. In normal and homozygote  
samples, normal and mutant allele are amplified 
respectively, and in heterozygote samples  
both normal and mutantalleles are amplified (Fig. 1). 
 
 
Table 2.  Primer sequences and mutations amplified by PCR. 
Mutation Sequence Primer 











in Exon 3 
5'-TCCAGAGCAGGGAGTAGTCTC-3' Ex3na 








5'-TCCACTGCAGCCATGTGCAC-3' Ex7na V281L 
5'-TCCACTGCAGCCATGTGCAA-3' Ex7ma 
5'-TTCGTGGTCTAGCTCCTCCTG-3' Ex81na Q318X 
5'-AGTTCGTGGTCTAGCTCCTCCTA-3' Ex81ma 
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Fig. 1. Polyacrylamide gel electrophoresis for exon 3. Lane 1 
is DNA marker, lanes 2 and 3 are related to the positive control 
for an 8 bp deletion in exon 3 (fragment size is 710 bp), lanes 4 
and 5 and lanes 10 and 11 are  related to heterozygote samples, 
lanes 6-9 and 12-15 are normal samples and lanes 16 and 17 are 
related a homozygote sample. 
 
 
RESULTS AND DISCUSSION 
 
 We totally analyzed 50 unrelated patients by 
allele specific PCR. Forty patients (80%) had these 
eight common mutations in the CYP21 gene and 10 
patients were normal for these mutations. Thirty 
cases had mutations in both chromosomes and 10 
samples had mutations in one allele. Twenty four 
patients (48%) were homozygous for each type of 
mutations (Table 3). From these patients, 20% were 
homozygote in I2G allele, 10% in 8 bp deletions in 
exon 3, 8% in I172N allele, 4% in E6 cluster, 4% in 
R356W and 2% was homozygous in Q318X as well 
as six cases were compound heterozygote. The most 
frequent mutations were found to be I2G (26%) and 
8 bp deletion in exon 3 (13%). The frequencies of 
other alleles were: I172N, 9%; V281L, 3%; exon 6 
cluster (I236N, V237E, and M239K), 4%; Q318X, 
9%; R356W, 5% and P30L, 0%. 
Seventy alleles had one of these mutations and 
twenty patients (48%) were homozygous for each 
type of mutation. The most frequent mutations were 
found to be I2G and 8 bp deletion in exon 3 
(G110∆8nt) in our populations (28% and  
13%, respectively). Also, our results differ          
from previous study in northeastern of Iran [10]. 
Since relative ethnic purity has been maintained by 
the natural geographic borders within Iran and by 
ancient culture, we expected these mutations to be 
homozygous. As we expected, nine genotypes of 
individuals predominantly were homozygous (Table 
3). Comparison of allele frequencies in different 
populations shows significant similarities with our 




  Table 3.  Genotype of individuals. 
Allele 1 Allele 2 Number of individuals 
8 bp deletion 8 bp deletion 5 
Q318X Q318X 1 
Q318X/8 bp deletion Q318X 1 
Q318X N 4 
R356W R356W 2 
R356W N 1 
Exon 6 cluster Exon 6 cluster 2 
I2G I2G 10 
I2G N 4 
I2G 8 bp deletion 2 
I2G Q318X 1 
I172N I172N 4 
I172N N 1 
V281L I2G 1 
V281L I2G/ V281L 1 
Total  40 







  Table 4.  Allele frequencies in different populations (%). 
Nationality 
Allele 
No. I2G V281L I172N 
8 bp 
deletion Q318X P30L R356W 
Exon 6 
cluster Ref. 
USA 394 31 9 10.0 4.0 4 2 4.0 4.0 11 
Sweden 400 27 6 20.0 1.0 2 2 4.0 5.0 12 
England 284 40 0 7.0 0.0 0 0 10.0 0.0 13 
French 258 21 17 9.0 4.0 4   6.0 14 
Italy 146 20 11 6.0  8 4  12.0 15 
Japan 102 29 1 14.0 0.0 0 0 14.0 4.0 16 
China 40 25  28.0  8  10.0 5.0 17 
Turkey 31 22 0 11.4 3.2 8 0 9.6 3.2 18 
Spain 58 26 17 2.0 5.0 4 2 4.0 5.0 19 
Chilly 126 19  7.0  9  11.0 10.0 20 
Mexico 94 48 9 12.0 2.0 4 9 7.0 1.0 21 
Brazil 74 25 4 19.0 1.0 11  8.0 5.0 22 
Argentina 72 18  15.0 4.0 14  6.0  23 
Fenland 102 12 3 29.0  2   10.0 24 
Iran 100 28 3 9.0 13.0 9 0 5.0 3.0 Our study 
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our population had not different from other 
populations and this mutation has high frequency in 
all over the world that may be a hotspot. But the 
frequency of 8 bp deletion in Exon 3 (G110∆8nt) 
had high frequency (13%) in our population in 
comparison with other populations that may be arise 
from an ancient mutation (founder effect) requiring 
to further investigations. The frequency of other 
mutations (P30L, Q318X, R356W, I172N, exon 6 
clusters) did not differ substantially from 
frequencies of other countries (Table 4).  
In cases that were homozygous for any type of 
mutations, they may be as a heterozygous for this 
mutation; therefore the frequency of these mutations 
may be higher than actual frequency because we did 
not detect the allele frequency for large deletion and 
conversions. Since the treatment and prenatal 
diagnosis of this disorder are feasible, setting up a 
molecular method for detection of these mutations 
with genetic counseling will help in prevention 
policies. We suggest that four mutations (I2G, 
G110∆8nt, I172N, and Q318X) should be screened 
by ASP method in our country at first and then other 
mutations can be analyzed. Further investigations 
are required to detect frequencies of other mutations, 
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